Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
<p>A and B. Evaluation of Vβ repertoire. The three distinct patterns were observed for Vβ repertoire in CD3+/IFN-γ+ T cells post IT. Pattern 1) the proportions of Vβ repertoire noticeably higher after IT relative to preIT PBMC (solid black arrows); Pattern 2) the proportions of Vβ repertoire t...
Na minha lista:
| Autor principal: | |
|---|---|
| Outros Autores: | , , , , , , , , , , , , |
| Publicado em: |
2025
|
| Assuntos: | |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| _version_ | 1849927634553667584 |
|---|---|
| author | Ulka N. Vaishampayan (15051039) |
| author2 | Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| author2_role | author author author author author author author author author author author author author |
| author_facet | Ulka N. Vaishampayan (15051039) Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ulka N. Vaishampayan (15051039) Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| dc.date.none.fl_str_mv | 2025-11-25T12:41:21Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30705755 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplementary_Figure_S1_from_Phase_II_Trial_of_Pembrolizumab_and_Anti-CD3_x_Anti-HER2_Bispecific_Antibody-Armed_Activated_T_Cells_in_Metastatic_Castration-Resistant_Prostate_Cancer/30705755 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |
| dc.title.none.fl_str_mv | Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>A and B. Evaluation of Vβ repertoire. The three distinct patterns were observed for Vβ repertoire in CD3+/IFN-γ+ T cells post IT. Pattern 1) the proportions of Vβ repertoire noticeably higher after IT relative to preIT PBMC (solid black arrows); Pattern 2) the proportions of Vβ repertoire that were marginally higher at mid- and/or post-IT relative to pre-IT PBMC (dashed black arrows); Pattern 3) large proportions of Vβ repertoire were either lower or similar at mid-IT or post-IT relative to preIT PBMC in all four patients tested. PreIT (pretherapy), midIT (preinfusion 5) postIT (1 week post infusion 8 of BATs).</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_08a3b59f20c665b810b9c7e033e35799 |
| identifier_str_mv | 10.1158/1078-0432.30705755 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30705755 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate CancerUlka N. Vaishampayan (15051039)Archana Thakur (15051042)Wei Chen (15051045)Abhinav Deol (15051048)Meera Patel (15051051)Kimberlee Dobson (15051054)Brenda Dickow (15051057)Dana Schalk (15051060)Amy Schienschang (15051063)Sarah Whitaker (15051066)Amanda Polend (15051069)Joseph A. Fontana (411960)Elisabeth I. Heath (15024674)Lawrence G. Lum (15051072)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsPhase II clinical trialsGenitourinary CancersProstate cancerImmunotherapyCellular immunotherapy<p>A and B. Evaluation of Vβ repertoire. The three distinct patterns were observed for Vβ repertoire in CD3+/IFN-γ+ T cells post IT. Pattern 1) the proportions of Vβ repertoire noticeably higher after IT relative to preIT PBMC (solid black arrows); Pattern 2) the proportions of Vβ repertoire that were marginally higher at mid- and/or post-IT relative to pre-IT PBMC (dashed black arrows); Pattern 3) large proportions of Vβ repertoire were either lower or similar at mid-IT or post-IT relative to preIT PBMC in all four patients tested. PreIT (pretherapy), midIT (preinfusion 5) postIT (1 week post infusion 8 of BATs).</p>2025-11-25T12:41:21ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30705755https://figshare.com/articles/figure/Supplementary_Figure_S1_from_Phase_II_Trial_of_Pembrolizumab_and_Anti-CD3_x_Anti-HER2_Bispecific_Antibody-Armed_Activated_T_Cells_in_Metastatic_Castration-Resistant_Prostate_Cancer/30705755CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307057552025-11-25T12:41:21Z |
| spellingShingle | Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Ulka N. Vaishampayan (15051039) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |
| status_str | publishedVersion |
| title | Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_full | Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_fullStr | Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_full_unstemmed | Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_short | Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_sort | Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| topic | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |